NEW YORK (GenomeWeb) – A survey of 132 oncologists has found that although around 70 percent of oncologists consider genomic testing to be an important advance in cancer, more than half also believe it is over-promoted because the technology’s value is “below expectations.”
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?
.
Be the first to comment